4.5 Review

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Journal

WORLD JOURNAL OF MENS HEALTH
Volume 40, Issue 1, Pages 11-29

Publisher

KOREAN SOC SEXUAL MEDICINE & ANDROLOGY
DOI: 10.5534/wjmh.210001

Keywords

Benign prostate hyperplasia; Erectile dysfunction; Men's health; Metformin; Prostate cancer; Reproductive function

Ask authors/readers for more resources

Metformin has various effects on men's health, with potential impacts on erectile dysfunction, steroidogenesis, spermatogenesis, prostate specific antigen, prostatitis, benign prostate hyperplasia, and prostate cancer. Studies on metformin's effects on these conditions are ongoing, with conflicting results on its effectiveness.
Metformin is the first-line oral antidiabetic drug that shows multiple pleiotropic effects of anti-inflamation, anti-cancer, anti aging, anti-microbia, anti-atherosclerosis, and immune modulation. Metformin's effects on men's related health are reviewed here, focusing on reproductive health under subtitles of erectile dysfunction (ED), steroidogenesis and spermatogenesis; and on prostate-related health under subtitles of prostate specific antigen (PSA), prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa). Updated literature suggests a potential role of metformin on arteriogenic ED but controversial and contradictory effects (either protective or harmful) on testicular functions of testosterone synthesis and spermatogenesis. With regards to prostate-related health, metformin use may be associated with lower levels of PSA in humans, but its clinical implications require more research. Although there is a lack of research on metform's effect on prostatitis, it may have potential benefits through its anti-microbial and anti-inflammatory properties. Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Many clinical trials are being conducted to investigate the use of metformin as an adjuvant therapy for PCa but results currently available are not conclusive. While some trials suggest a benefit in reducing the metastasis and recurrence of PCa, others do not show any benefit. More research works are warranted to illuminate the potential usefulness of metformin in the promotion of men's health.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available